Advancing Varenicline as a Treatment for Cannabis Use Disorder
推进伐尼克兰治疗大麻使用障碍
基本信息
- 批准号:10004604
- 负责人:
- 金额:$ 98.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-15 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAdverse eventAgonistAnteriorBasic ScienceCannabinoidsCannabisClinical TrialsCorpus striatum structureCuesDevelopmentDorsalEvaluationFrequenciesIndividualMeasuresMediatingMemoryNeurocognitionOutcomePatient Self-ReportPharmaceutical PreparationsPharmacodynamicsPharmacotherapyPlacebosPopulationPrefrontal CortexProcessResearchRewardsSafetyShort-Term MemorySystemTestingThalamic structureTobacco Use CessationUnited StatesUrinealcohol abuse therapyalcohol use disorderbaseblood oxygenation level dependent responseclinical effectcognitive enhancementcognitive functioncravingcue reactivitydrug developmentfollow-upillicit drug useimprovedmarijuana usemarijuana use disordermesolimbic systemneural circuitneuromechanismreceptorresearch clinical testingrestorationtobacco abstinencevareniclineweek trial
项目摘要
ABSTRACT
Cannabis is the most commonly used illicit drug in the United States. Although cannabis use is widespread and
basic science research on cannabinoids is well-developed, advancements in medication development for
cannabis use disorder (CUD) have been limited. Varenicline, a selective nicotinic nACH receptor partial agonist
of the α4β2 subtype and a full agonist of the α7 subtype, is arguably the most effective pharmacotherapy for
promoting tobacco abstinence, and has also shown promise for the treatment of alcohol use disorder. Varenicline
may improve cannabis use outcomes through multiple mechanisms, including interaction with the mesolimbic
dopamine system, enhancement of cognitive functioning, and restoration of inhibitory control. To date, however,
varenicline has not been evaluated in individuals specifically seeking treatment for CUD. In this UG3/UH3
application, we propose to rapidly yet thoroughly assess the utility of varenicline for CUD to potentially advance
varenicline through the FDA's drug development approval pipeline. In the UG3 component, we will conduct a
six-week, placebo-controlled proof-of-concept clinical trial of varenicline for CUD, paired with pre- and post-
evaluations of cognitive functioning and neural circuitry involved in cannabis cue reactivity and inhibitory control
to elucidate the pharmacodynamics of varenicline as a treatment for CUD. If milestones of the UG3 component
are met, the UH3 project will be an adequately powered 12-week clinical trial with follow-up to fully assess the
efficacy of varenicline in this population.
摘要
大麻是美国最常用的非法药物。尽管大麻的使用很普遍,而且
大麻类物质基础科学研究发达,药物开发进展
大麻使用障碍(CUD)一直受到限制。选择性烟碱型NACh受体部分激动剂varenicline
α4β2亚型和α7亚型的完全激动剂,可以说是治疗
促进戒烟,并在治疗酒精使用障碍方面显示出希望。伐尼克兰
可通过多种机制改善大麻的使用结果,包括与中脑边缘的相互作用
多巴胺系统、认知功能的增强和抑制控制的恢复。然而,到目前为止,
尚未对专门寻求CUD治疗的患者进行评估。在此UG3/UH3中
,我们建议快速而彻底地评估varenicline对CUD潜在进展的效用
Varenicline通过FDA的药物开发审批流程。在UG3组件中,我们将进行
Varenicline治疗CUD的为期六周的安慰剂对照概念验证临床试验,配对治疗前后
大麻线索反应性和抑制控制中涉及的认知功能和神经回路的评估
目的:阐明伐伦尼克林治疗慢性阻塞性肺疾病的药效学。如果UG3组件的里程碑
UH3项目将是一项动力充足的为期12周的临床试验,并进行跟踪以全面评估
伐伦克林在这一人群中的疗效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevin M Gray其他文献
Nicotine Therapy Sampling to Induce Quit Attempts Among Smokers Unmotivated to Quit
尼古丁治疗取样以诱导无戒烟动机的吸烟者尝试戒烟
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
M. Carpenter;John R. Hughes;Kevin M Gray;A. Wahlquist;M. Saladin;A. Alberg - 通讯作者:
A. Alberg
Kevin M Gray的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kevin M Gray', 18)}}的其他基金
A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder
N-乙酰半胱氨酸治疗青少年酒精使用障碍的概念验证试验
- 批准号:
10480914 - 财政年份:2018
- 资助金额:
$ 98.17万 - 项目类别:
A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder
N-乙酰半胱氨酸治疗青少年酒精使用障碍的概念验证试验
- 批准号:
10241372 - 财政年份:2018
- 资助金额:
$ 98.17万 - 项目类别:
A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder
N-乙酰半胱氨酸治疗青少年酒精使用障碍的概念验证试验
- 批准号:
9789787 - 财政年份:2018
- 资助金额:
$ 98.17万 - 项目类别:
13/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT MUSC
13/21 ABCD-美国联盟:MUSC 研究项目现场
- 批准号:
10596593 - 财政年份:2017
- 资助金额:
$ 98.17万 - 项目类别:
N-Acetylcysteine and Contingency Management for Youth Cannabis Use Disorder
N-乙酰半胱氨酸和青少年大麻使用障碍的应急管理
- 批准号:
9156301 - 财政年份:2017
- 资助金额:
$ 98.17万 - 项目类别:
N-Acetylcysteine and Contingency Management for Youth Cannabis Use Disorder
N-乙酰半胱氨酸和青少年大麻使用障碍的应急管理
- 批准号:
10087909 - 财政年份:2017
- 资助金额:
$ 98.17万 - 项目类别:
13/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT MUSC
13/21 ABCD-美国联盟:MUSC 研究项目现场
- 批准号:
9981294 - 财政年份:2017
- 资助金额:
$ 98.17万 - 项目类别:
13/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT MUSC
13/21 ABCD-美国联盟:MUSC 研究项目现场
- 批准号:
10379329 - 财政年份:2017
- 资助金额:
$ 98.17万 - 项目类别:
Advancing Varenicline as a Treatment for Cannabis Use Disorder
推进伐尼克兰治疗大麻使用障碍
- 批准号:
9249775 - 财政年份:2016
- 资助金额:
$ 98.17万 - 项目类别:
Advancing Varenicline as a Treatment for Cannabis Use Disorder
推进伐尼克兰治疗大麻使用障碍
- 批准号:
10202536 - 财政年份:2016
- 资助金额:
$ 98.17万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 98.17万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 98.17万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 98.17万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 98.17万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 98.17万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 98.17万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 98.17万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 98.17万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 98.17万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 98.17万 - 项目类别: